Literature DB >> 19353621

Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin.

Karin Beutel1, Ute Gross-Wieltsch, Thomas Wiesel, Udo Zur Stadt, Gritta Janka, Hans-Joachim Wagner.   

Abstract

BACKGROUND: Epstein-Barr virus (EBV) is one of the most frequent triggers of hemophagocytic lymphohistiocytosis (HLH). EBV-associated HLH (EBV-HLH) and ectopic infection of T cells has been particularly described in patients from Far East Asia. PROCEDURE: In a cohort of 12 children with EBV-HLH treated in Germany, the EB viral load was detected by real-time polymerase chain reaction in plasma and peripheral blood mononuclear cells (PBMC). Virological and clinical data were analyzed retrospectively.
RESULTS: Among the 12 mainly German patients, children with underlying immunodeficiencies as well as otherwise healthy individuals were affected. The clinical course ranged from a steroid-responding to a fatal disease despite intensive treatment. Increased EBV copy numbers in plasma and/or PBMC were found in all patients. Serial measurements reflected the course of the disease. Cell-type specific viral load was determined in seven patients and revealed EBV-infection of T cells in all of them. In contrast to the reported Asian patients a significant viral load was also found in B cells.
CONCLUSIONS: T cell infection appears to be a typical feature of EBV-associated HLH irrespective of patients ethnic background and the clinical course. Evaluation of cell-type specific infection should be considered when targeted therapy is applied. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19353621     DOI: 10.1002/pbc.22037

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  22 in total

1.  [Unexplained fever and B-symptoms in a young male Black African].

Authors:  T Weber; T Ettrich; M Christopeit; A Lindner; H J Holzhausen; A Oehme; D Arnold; H H Wolf; C Lübbert; A S Kekulé; H J Schmoll; K Werdan; H Ebelt
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

Review 2.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

3.  Are regimens containing rituximab effective in the initial treatment of Epstein-Barr virus-positive natural killer cell lymphoproliferative disease-associated hemophagocytic lymphohistiocytosis?

Authors:  Shinsaku Imashuku; Naoko Kudo; Kagekatsu Kubo; Akihiro Yachie
Journal:  Int J Hematol       Date:  2013-08-22       Impact factor: 2.490

Review 4.  Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County.

Authors:  Theodoros Kelesidis; Romney Humphries; Dawn Terashita; Shahrooz Eshaghian; Mary C Territo; Jonathan Said; Michael Lewinski; Judith S Currier; David Pegues
Journal:  J Med Virol       Date:  2012-05       Impact factor: 2.327

5.  Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review.

Authors:  Christos Stefanou; Christiana Tzortzi; Fotini Georgiou; Chrystalla Timiliotou
Journal:  BMJ Case Rep       Date:  2016-12-09

6.  Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1).

Authors:  Jeffrey I Cohen; Julie E Niemela; Jennifer L Stoddard; Stefania Pittaluga; Helen Heslop; Elaine S Jaffe; Kennichi Dowdell
Journal:  J Clin Immunol       Date:  2015-05-07       Impact factor: 8.317

Review 7.  How I treat hemophagocytic lymphohistiocytosis.

Authors:  Michael B Jordan; Carl E Allen; Sheila Weitzman; Alexandra H Filipovich; Kenneth L McClain
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

8.  Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases.

Authors:  Jan Rohr; Karin Beutel; Andrea Maul-Pavicic; Thomas Vraetz; Jens Thiel; Klaus Warnatz; Ilka Bondzio; Ute Gross-Wieltsch; Michael Schündeln; Barbara Schütz; Wilhelm Woessmann; Andreas H Groll; Brigitte Strahm; Julia Pagel; Carsten Speckmann; Gritta Janka; Gillian Griffiths; Klaus Schwarz; Udo zur Stadt; Stephan Ehl
Journal:  Haematologica       Date:  2010-09-07       Impact factor: 9.941

9.  Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.

Authors:  DeepakBabu Chellapandian; Rupali Das; Kristin Zelley; Susan J Wiener; Huaqing Zhao; David T Teachey; Kim E Nichols
Journal:  Br J Haematol       Date:  2013-05-21       Impact factor: 6.998

10.  Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11.

Authors:  Udo zur Stadt; Jan Rohr; Wenke Seifert; Florian Koch; Samantha Grieve; Julia Pagel; Julia Strauss; Brigitte Kasper; Gudrun Nürnberg; Christian Becker; Andrea Maul-Pavicic; Karin Beutel; Gritta Janka; Gillian Griffiths; Stephan Ehl; Hans Christian Hennies
Journal:  Am J Hum Genet       Date:  2009-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.